March 27, 2015

Company Name	3-D Matrix, Ltd.
Address	3-2-4, Kojimachi, Chiyoda, Tokyo
President	Kentaro Takamura
Code Number	7777
Contact	Director Tomoyuki Arai
TEL	+81 3 (3511)3440

[Delayed]Revision of Mid-term Business Plan (FY2014-FY2016)

(This original disclosure in Japanese was released on March 13, 2015 at 16:00 (GMT+9))

The company hereby announces that it revised its mid-term business plan (FY2014 to FY2016) which was previously announced on June 12, 2014. This revised mid-term business plan was submitted to Tokyo Securities Exchange today.

1. Reason of revision of mid-term business plan

FY 2014

There are three main reasons for making the revision for business forecast of our group in FY 2014, and the details are as follows:

・Revisions with the change of a development plan of absorbable local hemostat in Japan

An approval for manufacture and sales of the absorbable local hemostat (hereinafter called "this/the hemostat") in Japan had been expected, and the milestone payment revenue associated with the approval acquisition and sales revenue of the product after approval had been included in the business forecast for the fiscal year.

We had also been responding to the reviews of the Pharmaceuticals and Medical Devices Agency (hereinafter called "PMDA") since we filed an application for an approval for manufacture and sales of the product on May 31, 2011; however, in the process of the discussion with the PMDA on the scientific validity of the efficacy assessment, we concluded that a verification with higher accuracy in the efficacy of this hemostat is necessary to obtain the approval; therefore, we withdrew the application on March 13, 2015, and decided to reapply for an approval after conducting another clinical study.

As the revenue which was supposed to be earned from the approval for manufacture and sales of the product in this fiscal year cannot be expected due to the decision of the development plan change, we decided to revise our business revenue plan. We are currently planning to start a new clinical study in Japan in the next fiscal year. We are aiming at reapplying for an approval as soon as the clinical study is completed, but the specific timing has not been decided yet.

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ from the projected figures due to various subsequent factors.

・Revision with delayed conclusion of sales license agreement for absorbable local hemostat overseas

The upfront payment revenue from the sales license agreement for the hemostat with our distribution partner candidate mainly in Europe and the US and the sales of the product had been included in the business forecast of this fiscal year.

Although our group is in a negotiation process for partnerships with some companies, there are businesses which have been taking a long time from the stage of negotiating conditions to the conclusion of the contract via due diligence and which require more negotiations in terms of the conditions. We fully examined, from the third quarter to the fourth quarter of this year, the progress of these businesses for the revenue in this fiscal year, but judged that the contract would not be concluded by the end of this fiscal year.

The upfront payment revenue and sales revenue of the product cannot be expected to be earned in this fiscal year due to the progress status of the negotiations; therefore, we decided to revise the business revenue plan.

・Revision of expense and profit amounts corresponding to changes of business revenue status

Among the expense in this fiscal year, the sales cost is expected to decrease with the changes of the above-stated revenue status. In addition, as we had been working on mainly reviewing and lowering the expenses including the sales expense and general administrative expenses, we decided to revise the business expense plan. A downward revision will be made to the business revenue forecast in this fiscal year from 10,418 million yen to 51 million yen, leading to a decrease in each profit amount; therefore, the downward revision will be made to each profit forecast including business profit.

FY 2015

As a conventional business revenue goal, we planned to earn an upfront payment from the contract for this hemostat in Japan and overseas (Europe and the US, Asia, Latin America, etc.), milestone payment revenue, sales of the product, and milestone payment revenue associated with the development of other pipeline products and their sales revenues.

In this revision of the plan, we plan to conclude the sales license agreement for this hemostat with a distribution partner candidate in Europe in FY 2015, which had been initially planned for FY 2014, as well as to receive the upfront payment and sales revenue of the product associated with this agreement.

In Asia and Latin America, we are planning to receive the upfront payment associated with sales license agreement, milestone payment revenue, and sales of the hemostat. Based on the above-stated circumstances, the business revenue goal has been revised from 14,307 million yen to 3,694 million yen, and each profit goal including the target amount of business profit has also been revised.

FY 2016

As a conventional business revenue goal, we planned an upfront payment from the contract for this hemostat in Japan and overseas (Europe and the U.S., Asia, Latin America, etc.), milestone payment revenue, sales of the product, and milestone payment revenue associated with the development of other pipeline products and their sales revenue.

In this revision of the plan, we plan to conclude the sales license agreement for this hemostat with a distribution partner candidate in the U.S. in FY 2016, which had been initially planned for FY 2014, as

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ from the projected figures due to various subsequent factors.

well as to receive the upfront payment and sales revenue of the product associated with this agreement.

In the midterm business plan, we also expect to acquire an approval for this hemostat in Japan after the reexamination of the development plan and to receive milestone payment revenue associated with this approval.

We are also planning to receive the sales revenue of the product and milestone payment revenue associated with the development progress of other pipeline products including mucosa-elevating material in Europe, Asia, and Latin America, which have been continuously planned from the previous fiscal year. Based on the above-stated circumstances, the business revenue goal has been revised from 18,473 million yen to 11,345 million yen, and each profit goal including the target amount of business profit has also been revised.

2. Earning forecast of this fiscal year and future targets

(Millions of yen)

	Business revenue	Operating income (loss)	Ordinary income (loss)	Net income (loss)
FY2013 (actual)	107	(1,518)	(1,523)	(1,525)
FY2014 (original forecast)	10,418	4,483	4,466	3,564
FY2014 (revised forecast)	51	(1,984)	(1,884)	(2,080)
FY2015 (original target)	14,307	6,796	6,779	4,678
FY2015 (revised target)	3,694	731	714	171
FY2016 (original target)	18,473	8,213	8,196	5,450
FY2016 (revised target)	11,345	4,377	4,361	3,000

Note: Figures above are extracted from the company's revised mid-term business plan.

3. Premises for earning forecast of mid-term business plan

With changes of the development plan for the hemostat in Japan and of the timing of business collaboration in Europe and the US, the timing of allocation of the revenue has to be revised, but there is no big change in the "midterm business plan" announced in June 12, 2014 other than some related sections.

For the financial plan, we are going to continuously strengthen our financial ground, but so far we have secured research and development expenses, etc. for each pipeline product by fund raising overseas in July 2014. In addition, as a way of agile fund-raise, we have an ongoing commitment line contract of 300 million yen as an upper limit with Sumitomo Mitsui Banking Corporation. We have also set the borrowing facility of 1 billion yen in total consisting of 500 million yen each with Sumitomo Mitsui Banking Corporation and Mizuho Bank, Ltd., and 200 million yen is currently leveraged out of the 1 billion yen.

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ from the projected figures due to various subsequent factors.

4. Others

For details other than the above, please refer to the attached material "Mid-term business plan (revised version)".

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ from the projected figures due to various subsequent factors.

March 13, 2015

<Reference Information>

Company Name	3-D Matrix, Ltd.
Address	3-2-4, Kojimachi, Chiyoda, Tokyo
President	Kentaro Takamura
Code Number	7777
Contact	Director Tomoyuki Arai
TEL	+81 3 (3511)3440

Mid-Term Business Plan (FY2014-FY2016)

1. Mid-term business plan over the next three years

(1) Review of FY2013 (previous fiscal year), as of the announcement of this business plan.

During FY2013, 3-D Matrix group continued to focus on developing medical devices using self-assembling peptide, which is the group's core technology. As for surgical hemostat (TDM-621), the primary product in the product pipeline, the group has applied to the Pharmaceuticals and Medical Devices Agency, Japan, (PMDA) for manufacturing and marketing approval and has been consulting with the U.S. Food and Drug Administration (FDA) in order to launch a clinical trial in the U.S.

In Europe, the group is launching production and working to convince leading medical facilities to start using the hemostat as the product obtained CE marking on January 14, 2014, making it possible to manufacture and sell the hemostat in EU member countries. Furthermore, this CE marking enables the group to apply for manufacturing and marketing approval without conducting clinical trials in various countries in Asia-Pacific and Latin America, where CE marking is recognized as a reference regulatory agency approval.

The group has also launched efforts to convince several leading facilities to conduct clinical researches in Europe and is moving forward with projects to get the hemostat listed in insurance reimbursement system in each country and to increase its use at various medical facilities. At the same time, the group is moving forward with negotiations regarding distribution license agreements with sales partners.

In other regions, the company's subsidiary in Singapore, 3-D Matrix Asia Pte. Ltd. concluded an exclusive distribution license agreement for Indonesia in May, 2013 with Indonesia-based PT. Tegushindo Lestaritama. The group continues to prepare for expanding the business of TDM-621 including Asia-Pacific, China, and Latin America.

As for the dental bone filler (TDM-711), the product has been used in 15 cases of clinical trial in the U.S. and the related follow-up has been completed. Based on these results, the group is continuing consultations with FDA regarding launching a pivotal clinical trial.

The group is also moving forward with discussions with PMDA to launch a clinical trial for the

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ from the projected figures due to various subsequent factors.

endoscopic mucosal resection aid (TDM-641).

Furthermore, the group and National Cancer Center are jointly conducting a project which is to cure triple negative breast cancer by nucleic acid-based drugs. The project was nominated as one of the projects of Program Year 2011 Grants-in-Aid for Scientific Research by Ministry of Health, Labour, and Welfare, and the company received research grant, which was recognized as business revenue.

Another joint research project with New Energy and Industrial Technology Development Organization (NEDO), which is to develop new device promoting automatic regeneration of tissues with fewer cells in vivo, has been proceeding since FY2010.

As a result, consolidated operating revenue for FY2013 totaled 107,161 thousand yen (up 75,148 thousand yen from the previous year), with ordinary loss of 1,523,867 thousand yen (compared to ordinary loss of 977,511 thousand yen for the previous year), and net loss of 1,525,374 thousand yen (compared to net loss of 978,331 thousand yen for the previous year).

(2) Overview and background of mid-term business plan

Basic policy of mid-term business plan

3-D Matrix group has been developing medical devices and drugs in the field of surgery, regenerative medicine, and DDS with its core technology, self-assembling peptide.

Based on a search of application pipeline leveraging this fundamental technology, our basic policy is to develop and market medical devices and to secure revenue through products sales. Products are sold to business partners to whom we grant distribution rights, and we also aim to secure revenues from initial income or milestone income as compensation for the distribution rights.

Detailed plans are as follows.

- Focus and specialize on commercialization strategy and business planning functions, and aim to strengthen lineup of our product pipelines
- Bring multiple products to market quickly to secure stable product sales revenues
- Strengthen our business model, which is to supplement manufacturing and marketing/sales functions through partnerships

Mid-term business targets

- Obtain manufacturing and marketing approval of hemostat, secure income through marketing/sales of product, and promote to increase market share
- Establish a framework for overseas development and marketing/sales of hemostat, through business partnerships
- Complete preclinical trial of endoscopic mucosal resection aid and embolism, start clinical trial, and enter into business partnership
- Complete clinical trial of dental bone filler, enter into business partnership in U.S., and establish structure for manufacturing and marketing

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ from the projected figures due to various subsequent factors.

(3) Business progress / forecast and those premises

- Our group carries out research and development of main multiple pipeline products using self-organizing peptide technology in the fields of surgery and regenerative medicine. We also have medical product business by launching these pipeline products and obtaining business revenue through sales.
- A clinical study for absorbable local hemostat being developed for the field of surgery was completed, and since the application of the approval for manufacture and sales of the product in May 2011, the PMDA had reviewed the result. However, we decided to conduct another clinical study during FY 2015 to assess the efficacy with more accuracy for an early approval, and change the timing so as to obtain the approval after FY 2016. We have concluded a contract for manufacturing and sales with Fuso Pharmaceutical Industries, Ltd. and are currently developing a system for launch of the products. For sales, we have concluded an exclusive sales license agreement with the company to strengthen the manufacturing and sales system. We consider it an important issue to acquire an approval for manufacture and sales of the products and start selling them in Japan as soon as possible.
- For the overseas development of absorbable local hemostat, we have obtained an approval for CE marking in January 2014 in Europe and are in the process of collaboration with our business partners and product selling. In the U.S., we are in the process of preparing the study protocol of a clinical study which is planned to be started in FY 2015. In Asia, by utilizing CE marking, we obtained an approval for the registration of medical device products in September 2014 in Singapore. We have filed an application for registration of medical device products in Indonesia and South Korea. We will continuously promote the development of a system for stable product manufacture and supply.
- In terms of other pipeline products which have been promoted with the hemostat, a clinical study for dental bone filler has been started in the U.S. In addition, we concluded an exclusive sales license agreement for mucosa-elevating material with Fuso Pharmaceutical Industries, Ltd. in February 2012, and a clinical study was started in December 2014. We consider it important to conduct a clinical study for embolization material in an early period by incorporating the safety data of the hemostat and collecting the efficacy data.
- In order to search for and obtain more pipeline product candidates, we are trying to acquire applied technologies by conducting joint research with universities and research institutions, and developing products for the field of drug delivery system (DDS).
- Our group's pipeline products have been developed as medical devices. The development period to their launch is shorter than that for drugs, and the development cost can also be lowered, but a certain or more amount of expenses is required for the development. Funds including upfront payment by contract, milestone payment revenue, and each finance fund have been secured as a prerequisite for this development.

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ from the projected figures due to various subsequent factors.

2. Earning forecast of this fiscal year and future targets

(Millions of yen)

	Business revenue	Operating income (loss)	Ordinary income (loss)	Net income (loss)
FY2013 (actual)	107	(1,518)	(1,523)	(1,525)
FY2014 (forecast)	51	(1,984)	(1,884)	(2,080)
FY2015 (target)	3,694	731	714	171
FY2016 (target)	11,345	4,377	4,361	3,000

Note) Figures above are extracted from the company's revised mid-term business plan.

Premises for earning forecast

- Business revenue

  Our group plans the business revenue by estimating the timing of revenue allocation based on the development plan of each pipeline product, and estimates the revenue amount in view of the market size, competition status, superiority, most recent market trend, negotiation status, and the like. As a business revenue forecast from FY 2014 to FY 2016, we will sum up all the estimates including milestone payment revenue associated with gaining an approval for manufacture of absorbable local hemostat in Japan and overseas, sales of the product after its launch in Japan and overseas, overseas revenue of the product, and upfront payment by contract, milestone payment revenue, and sales of other pipeline products.

- Operating cost

  We categorize business expense of our group into sales cost, research and development expense, sales expense, and general administrative expense, and each expense is determined by summing up the related expenses.

  Cost of sales

  The cost of sales is determined by summing up peptide raw material cost, each material cost, fees for consignment of manufacture, etc. base on the sales estimate of each product.

  Research and development expense

  The research and development expense is determined by summing up the expense by project of each pipeline product under development. Compared with the drug development expenses, the development expenses of medical devices can usually be reduced, but the research and development expense for absorbable local hemostat is determined by summing up the development expenses in Europe and the U.S., test expenses for commercialization of the product, and review expenses for manufacture.

  Selling and general administrative expense

  For selling and general administrative expense, we take each of the past expense amount into consideration, and calculate the estimate in line with the future business plan.

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ from the projected figures due to various subsequent factors.

Personnel planning

We design manpower planning to develop an appropriate system in line with business expansion, an increase in number of products handled, and necessary operation expansion associated with increased pipeline products.

- Capital investment plan

We design capital expenditure plan by estimating the installation of new manufacture equipment for the launch of the hemostat in the market and planned expansion of existing testing equipment to deal with continuous research and development.

- Financial plan

For the financial plan, the research and development expense for clinical studies for pipeline products under development mainly has more weight than other expenses, and we are going to continuously strengthen our financial ground for necessary financial plans. We have secured the research and development expense, etc. for each pipeline product by raising funds overseas in July 2014. In addition, as a way of agile fund raise, we have an ongoing commitment line contract of 300 million yen as an upper limit with Sumitomo Mitsui Banking Corporation. We have also set the borrowing facility of 1 billion yen in total consisting of 500 million yen each with Sumitomo Mitsui Banking Corporation and Mizuho Bank, Ltd., and 200 million yen is currently leveraged out of the 1 billion yen. Our group is going to examine the various ways of fund raising to secure necessary funds and to continuously establish our stable management base.

- Earning forecast

Contrary to our earning forecast, uncertainties ascribable to various factors including the further development status of the pipeline products, negotiation status with business partners, sales status of the products after their launch in the market may occur.

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ from the projected figures due to various subsequent factors.

3. Other reference information

○ Development status of main pipelines

		Region	Basic research / Evaluation test	Preclinical trial	Clinical trial	Applying approval of manufacturing & marketing	Approval of manufacturing & marketing	Insurance listed	Distribution
Surgery	Hemostat (TDM-621) (*2)	EU							
		Japan							
		US							
		Korea							
		Latin America							
		China							
	Endoscopic Mucosal Resection Aid (TDM-641)	Japan							
	Embolism (TDM-631)	Japan							
Regenerative Medicine	Dental Bone Filler (TDM-711) (*3)	US							
	Wound Treatments (TDM-511)	US							

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ from the projected figures due to various subsequent factors.

(Note) 1  indicates a development plan, and  indicates a plan already conducted  ,  and  indicate the development plan goals in FY 2014, FY 2015, and FY 2016, respectively.

2 Absorbable local hemostat

Europe: The product has met the requirements of CE marking in January 2014 and will be distributed from FY 2014.

Japan: A clinical study was completed in April 2011, and application for an approval for manufacture and sales of the product was filed in May 2011. However, in March 2015, we changed the plan to conduct another clinical study and reapply for an approval.

U.S.: We are in the process of discussion with the Food and Drug Administration (FDA) on the protocol for a clinical study, and are planning to start the clinical study in FY 2015 and to sell the product after FY 2016.

South Korea: We decided to register the product as the one with CE marking and filed an application for it to the regulatory authority in January 2015. The registration of the product is planned to be approved in FY 2015.

Latin America (Brazil, Mexico, Columbia, etc.): The application for registration of the product was filed as the one with CE marking in Columbia in March 2015, and it has been planned that application for registration as the one with CE marking would be filed also in Brazil and Mexico during the first half of FY 2015. Although the product is expected to be launched in these countries in FY 2015, the timing of the launch could be after FY 2016 in some countries.

Other Asian regions: The product has been approved for registration as a medical device in Singapore. It was also applied for the registration in Indonesia in July 2014 and is currently under review. The approval is planned to be obtained in FY 2015.

3 Dental bone filler

In September 2010, our subsidiary filed an IDE application to the FDA for the start of a clinical study, obtained an IDE approval in July 2011, and started the clinical study in February 2012.

4 Wound healing material

A subsidiary in the U.S. submitted the premarket notification 510(k) to the FDA in October 2014. The product was approved by the FDA in February 2015.

5 Field of DDS

We are also developing products for the field of DDS. This is the development of drugs containing our peptide as a carrier, and because we are not going to engage in this commercialization alone and the developed technology (license) will be mainly provided to major pharmaceutical companies, this is not included in the above-stated pipeline product development status.

Main premises, issues, and specific plans of each pipeline to achieve plan in each fiscal year are stated as follows.

● Hemostat (TDM-621)

Feature : To stop bleeding by blocking contact surface with applying TDM-621,which has a feature to self-assemble, form nano-fiber, and gelate upon contact with body fluid such as blood ,to bleeding area in surgery operation

Target : Blood effusion upon surgery operation

Market : Europe, US, Japan, Asia, Latin America, etc.

Stage : Europe: We obtained CE marking in January 2014.
US: A clinical study is planned to be started in FY 2015.
Japan: In March 2015, the plan was changed as follows: a new clinical study will be performed, and the approval will be reapplied.
Asia: An approval for registration as a medical device was obtained in Singapore in September 2014. The same application was filed in Indonesia in July 2014, and is currently under review. The same application was filed in South Korea in January 2015, and is currently under review.
South America: Application for registration of the product as a medical device was

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ from the projected figures due to various subsequent factors.

filed in Columbia in March 2015.
The same application is planned to be filed in Brazil and Mexico during FY 2015.

Premise : The prerequisites include the upfront payment associated with a planned acquisition of each approval and product sales in assumed surgery field.

Issue : We should respond to the review at each validation associated with preparation for registration as a medical device with CE marking in each country. In a clinical study newly planned in Japan, we need to perform an efficacy assessment with higher accuracy, apply for an approval, and respond to the review for the study.

Specifics : We are discussing and preparing for the acquisition of the data for assumed endpoints and the plan of a clinical study to be performed.

● Endoscopic Mucosal Resection Aid (TDM-641)

Feature : To foam an elevation by injecting TDM-641, which has a feature to self-assembly gelate, into submucosal membrane, in order to raise cancer area to resect in endoscopic mucosal resection or endoscopic submucosal dissection for stomach or esophagus cancer

Target : Endoscopic Mucosal Resection, Endoscopic Submucosal Dissection

Market : Japan

Stage : Clinical study phase
TDM-641 uses a self-organizing peptide as a raw material, which is the same as that of TDM-621 but with a different concentration; therefore, the safety test result confirmed for TDM-621 can be incorporated as that for TDM-641. We are currently carrying out necessary preparations for a clinical study to confirm the safety of TDM-641.

Premise : We need to conduct a clinical study based on the result of pre-clinical studies, acquire an approval for manufacture and sales, and have the product covered by insurance.

Issue : We will reexamine test methods to identify more evident efficacy of the product and the development of product materials to secure the superiority of the product.

Specifics : We are currently discussing and preparing for necessary tests and developing the product to be able to finish the clinical study in an early period.

●Embolism (TDM-631)

Feature : Expected to use in hepatic or uterine artery embolization for liver or uterine cancer. To obstruct artery which is nutrient vessel for cancer, block nutrient and destroy cancer, by injecting TDM-631, which has a feature to self-assembly gelate, into artery as embolizing material through a catheter and by embolizing intravascular lumen physically.

Target : Hepatic artery embolization, Uterine artery embolization

Market : Japan

Stage : Preclinical trial

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ from the projected figures due to various subsequent factors.

Premise	:	Clinical trial conducted based on preclinical trial data, Manufacturing and
Issue	:	marketing approval acquired, Insurance listed To show sufficient test results in order to obtain an approval of clinical trial
Specifics	:	To prepare sufficient test results in order to start clinical trial early

● Dental Bone Filler (TDM-711)

Feature	:	To keep three dimensional structure by self-assembly gelating and foaming nano-fiber, to make a condition where a cell grow in vivo, and to support tissue regeneration, in order to rebuild alveolar for regressive alveolar with periodontal disease to be operated with implant procedure.
Target	:	Alveolar rebuilding operation
Market	:	U.S.
Stage	:	Clinical trial
Premise	:	Clinical trial finished, Manufacturing and marketing approval acquired in the U.S.
Issue	:	To prepare sufficient data and additional test results if additional data or test are requested by FDA
Specifics	:	To conduct additional test with an advice of medical consultant in U.S. about necessary data or test to FDA reference

●Wound Treatments (TDM-511)

Feature	:	To stimulate wound healed due to regenerative environment for dermal tissue made in dermal wound by self-assembly gelating and foaming nano-fiber.
Target	:	Mild-to-moderate skin wound
Market	:	U.S. and Europe
Stage	:	Acquisition of approval in the U.S.
Premise	:	The review agency has confirmed the efficacy and safety of the product.
Issue	:	Under examination for future commercialization (please note that this pipeline product has not been allocated in the revenue target at this point).
Specifics	:	We have started to examine the issues including alliance for commercialization.

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ from the projected figures due to various subsequent factors.

<Glossary>

* Self-assembling Peptide

Peptide group forming nano-fiber by peptide molecules regularly assembled under physiological condition

* Endoscopic Submucosal Dissection (ESD)

A relatively new surgical procedure for early stage stomach or esophagus cancer, which is to dissect cancer inch by inch with various electric knives after injecting liquid like hyalurnoic acid around tumor and raising submucosal resect area. It is possible to resect large lesion collectively different from endoscopic mucosal resection because resection is operated by electric knives and resecting area can be decided freely.

* Endoscopic Mucosal Resection (EMR)

An endoscopic operation of early stage cancer or polyp, which is resecting mucosal tissues at a depth of submucosal membrane by passing high-frequency electric current through wire called snare without a damage to submuscle layer.

* Bridging

To apply for pharmaceutical approval by sharing data of preclinical or clinical trial between countries with different pharmaceutical regulations

* DDS

Abbreviation of Drug Delivery System, which is a system, device, or technique to make proper drug behave at proper point during proper term.

* IDE

Abbreviation of Investigational Device Exemption, which is an application of special exemption to FDA relating to clinical trial of new medical device.

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ from the projected figures due to various subsequent factors.

Consideration

This disclosed statement is described future business plan, which is provided for informational purposes to investors and should not be construed as a solicitation of an investment. You should rely on your own examination of us before evaluation of our business plan and investing in any securities issued by our company.

Furthermore, our company does not guarantee the probability of any future results, performance, or achievements regarding business plans, business goals, and others, and is not responsible for any future results, performance, or achievements.

All contents relating to future described in this disclosed statement, including but not limited to business plans and goals, are examined by our company with available information at this moment. Actual results, performance, achievements, or financial position are expected to be affected by a change of premises of our business plans including a change of future economy or other factors and are possible to be widely different from contents described in this disclosed statement.

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ from the projected figures due to various subsequent factors.